SI-BONE Inc
NASDAQ:SIBN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth $-5.96 (142% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -31 | $14.32 |
0%
|
| Industry Average | 12.9 | $-5.96 |
-142%
|
| Country Average | 14.4 | $-6.64 |
-146%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$464.3m
|
/ |
Jan 2026
$-16.6m
|
= |
|
|
$464.3m
|
/ |
Dec 2026
$10.2m
|
= |
|
|
$464.3m
|
/ |
Dec 2027
$19.1m
|
= |
|
|
$464.3m
|
/ |
Dec 2028
$34.9m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
SI-BONE Inc
NASDAQ:SIBN
|
625m USD | -31 | -33.1 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
166.7B USD | 14.5 | 26.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.3B USD | 43.9 | 57.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
129.4B USD | 20.4 | 39.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.1B USD | 13.1 | 23.6 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
90.4B USD | 18.6 | 31.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.2B EUR | 11.4 | 20.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 24 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.5B USD | 31 | 43.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.2B USD | 10.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.8B USD | 11.6 | 16.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
SI-BONE Inc
Glance View
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.
